

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Laekna, Inc.

來凱醫藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2105)

CHANGE OF THE COMPOSITION OF THE NOMINATION AND CORPORATE GOVERNANCE COMMITTEE

The board (the “**Board**”) of directors (the “**Directors**”) of Laekna, Inc. (the “**Company**”) announces that with effect from December 12, 2025, Ms. XIE Ling, an executive Director, and Mr. ZHOU Jian, an independent non-executive Director, have been appointed as a member of the nomination and corporate governance committee of the Company (the “**Nomination and Corporate Governance Committee**”). Following the above changes, the Nomination and Corporate Governance Committee shall consist of five members, namely Dr. LU Chris Xiangyang, Dr. YIN Xudong, Dr. LI Min, Ms. XIE Ling and Mr. ZHOU Jian, with Dr. LU Chris Xiangyang serving as the chairperson of the Nomination and Corporate Governance Committee.

The above changes have been made in compliance with the Corporate Governance Code set out in Appendix C1 to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

By order of the Board
Laekna, Inc.
Dr. LU Chris Xiangyang
Chairman

Hong Kong, December 12, 2025

As at the date of this announcement, the Board comprises Dr. LU Chris Xiangyang, Ms. XIE Ling and Dr. GU Xiang-Ju Justin as executive Directors; Dr. WANG David Guowei and Mr. SUN Yuan as non-executive Directors; and Dr. YIN Xudong, Dr. LI Min and Mr. ZHOU Jian as independent non-executive Directors.